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ABSTRACT 
The aim of present study is to examine the in vitro-in vivo correlation (IVIVC) of immediate release product. Atenolol 100mg and 
its brands of immediate release dosage forms. Atenolol is clearly classified into BCS class III, and could be evaluated under bio 
waiver conditions. The in vitro parameters employed were hardness, weight uniformity, friability, disintegration time, absolute 
drug content, dissolution rate (in 0.1 N Hydrochloric acid, phosphate buffer and acetate buffer at 37ºC), and dissolution 
efficiencies were also analyzed. The in-vitro dissolution study was performed on the brands, according to FDA,USP  dissolution 
profile in three different PH (1.2),(4.5), and (6.8) at 37ºC, using the USP apparatus II,  then f1, f2 were determined for the time 
intervals of 10, 15, 30, 45 and 60 minutes, and dissolution efficiencies were calculated.  MINITAB 14 statistical program used for 
in vitro-in vivo correlation, level A was done for reference product. A non linear relation was established which is typical for 
immediate release formulation, of class III. 
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INTRODUCTION 
Bio-equivalence is defined as the absence of a 
significant difference in the rate and extent to which 
the active ingredient or active moiety in pharmaceutical 
equivalents or pharmaceutical alternatives becomes 
available at the site of drug action when administered 
at the same molar dose under similar conditions in an 
appropriately designed study. If two medicines are 
bioequivalent there is no clinically significant 
difference in their bioavailability
1
. 
Development and optimization of formulation is an 
integral part of manufacturing and marketing of any 
therapeutic agent which is indeed a time consuming 
and costly process. Optimization process may require 
alteration in formulation composition, manufacturing 
process, equipment and batch sizes. If these types of 
changes are applied to a formulation, studies in human 
healthy volunteers may be required to prove that the 
new formulation is bioequivalent with the old one
2
. 
Certainly, implementation of these requirements not 
only halts the marketing of the new formulation but 
also increases the cost of the optimization processes. It 
would be, desirable, therefore, to develop in vitro tests 
that reflect bioavailability data. A regulatory guidance 
for both immediate- and modified-release dosage forms 
has been, therefore, developed by the FDA to minimize 
the need for bioavailability studies as part of the 
formulation design and optimization
3
. IVIVC can be 
used in the development of new pharmaceuticals to 
reduce the number of human studies during the 
formulation development. 
Atenolol is a selective β1 receptor antagonist, a drug 
belonging to the group of beta blockers (sometimes 
written β-blockers), a class of drugs used primarily in 
cardiovascular diseases. Introduced in 1976, atenolol 
was developed as a replacement for propranolol in the 
treatment of hypertension. It works by slowing down 
the heart and reducing its workload
4
. 
 
MATERIALS AND METHODS 
ATN reference standard USP, Mfg. August 2013, Exp. 
July 2018, and three different brands of ATN tablets 50 
mg obtained from local market, DW and Methanol 
99.8% (Sharlau, Spain). 
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Uniformity of weight test 
Twenty randomly selected tablets were weighed. The 
average weights were determined. The tablets were 
weighed individually and the percentage of deviation 
of its weight from the average weight was determined 
for each tablet
4
.  
Hardness test 
The hardness of 10 tablets randomly selected from 
each batch was determined on an automatic tablet 
hardness tester. The crushing strength of uncoated 
tablets is accepted within 4-8 kg/cm
2
. 
Friability test 
20 tablets previously freed of dust were weighed 
together before transferring to a friabilator set to run 
for 4 min at 25 rpm. Thereafter they were removed, 
dusted and reweighed: 
% Friability =
𝑊𝑖 –  𝑊𝑓
𝑊𝑖
𝑋100 
Where, Wi is the initial weight and  
Wf the final weight of the tablets. 
Disintegration time test 
According to official monograph determination of 
disintegration time for uncoated tablets was adopted 
using a disintegrating apparatus and the medium was 
distilled water at 37±1
o
C. Six tablets were used for the 
determination. Accepted range for the uncoated tablet 
up to 30 minutes
5
. 
Absolute drug content 
Five pre-weighed tablets were crushed; the equivalent 
weight of a tablet was weighed out and dissolved in 
100ml volumetric flask and filtered. The absorbance 
reading was determined using UV-visible 
spectrophotometer at 273 nm
4
. 
In vitro dissolution test 
Volume of 900 ml of each buffer was employed. 
Dissolution testing was performed using Tablet 
Dissolution Tester (USP Apparatus 2) at 75 rpm for 
class III test and reference products, temperature will 
be adjusted to 37±0.5
o
C. Twelve dosage units of each 
product test and reference were evaluated in the three 
media. Sample aliquots of 10 ml were taken manually 
with syringes. Samples were withdrawn at specified 
time intervals (10, 15, 30, 45, and 60 min) and replaced 
with 10 ml of appropriate medium. Withdrawn samples 
were filtered using 0.45-μm Millipore Filters, then 5 ml 
taken after filtration by volumetric pipette (3ml taken 
when use HCL buffer solution, and 1ml taken in case 
of acetate and phosphate buffer, and diluted to 50 ml). 
A UV–visible spectrophotometer was used to analyze 
dissolved drug in dissolution testing. Scanning of 
wavelength done in each buffer, and spectrum recorded 
between 200-800nm, and percentage of drug dissolved 
calculated
6
. 
Buffers preparation 
Simulated gastric fluid (SGF), simulated intestinal fluid 
(SIF), and acetate buffer PH (4.5) were prepared 
according to instructions in USP test solution. All 
media were prepared without enzymes, as follows: 
Simulated gastric fluid (SGF) PH (1.2) 
To prepare hydrochloric acid 0.1N, 8.5 ml was taken 
from concentrated HCL (37%) and volume completed 
to 1000 ml by distilled water
7
. 
 
Simulated intestinal fluid (SIF) pH (6.8) 
Potassium phosphate monobasic KH2PO4 0.2 M was 
prepared by dissolving 27.22 g in water, and volume 
diluted to 1000 ml by distilled water. Then sodium 
hydroxide 0.2 M prepared by dissolving 8g in water 
and volume diluted to 1000 ml by distilled water. 250 
ml from Potassium phosphate monobasic KH2PO4 0.2 
M was placed into 200 ml volumetric flask, also 112 
ml taken from sodium hydroxide 0.2M and volume 
completed to 1000 ml with distilled water
7
. 
Acetate buffer pH (4.5) 
Firstly acetic acid 0.2N was prepared from 
concentrated acetic acid 99.93%. Measured amount of 
116 ml was taken and diluted with distilled water. Then 
2.99 g of sodium acetate (NaC2H3O2) taken, and placed 
in 1000 ml volumetric flask, 14ml from acetic acid was 
added and volume completed to 1000 ml by distilled 
water
8
. 
Preparation of standard stock solutions 
Standard stock solutions of Atenolol in HCL, 
phosphate and acetate buffers were prepared by 
dissolving 100 mg of standard in 100 ml volumetric 
flask using acetate and phosphate buffers as solvents to 
give concentration of 1000 μg/ml, 5 ml diluted to 100 
ml volumetric flask (50μg/ml), using 50 ml volumetric 
flask to give serial concentration of standard curve
8
. 
Statistical analysis 
All dissolution data evaluated using Excel spread sheet, 
and the results will be plotted for each brand. Average 
of % content of active pharmaceutical ingredient (API) 
dissolved in each media of 12 tablets will be taken and 
a plot of % of (API) dissolved against time will be 
drawn to represent the dissolution profile .The 
dissolution profile for local brand will be compared to 
that of the reference drug
9
. 
If they are similar the similarity factor, f2 equal to or 
more than 50.This means that they are equivalent, if 
it’s less than 50 they are not equivalent. 
f1 = {[3t=1n | Rt - Tt| ]/[3t=1n Rt ]}C 
f2 = 50 C log {[1+(1/n)3t=1n ( Rt - Tt )2 ] -0.5C 100} 
Similarity factor f2 has been adopted by FDA and the 
European Agency for the Evaluation of Medicinal 
Products (EMEA) by the Committee for Proprietary 
Medicinal Products (CPMP) as a criterion to compare 
the similarity of two or more dissolution profiles. 
Similarity factor f2 is included by the Centre for Drug 
Evaluation and Research (CDER) in their guidelines 
such as guidance on dissolution testing of immediate 
release solid oral dosage forms (FDA, 1997) and 
guidance on waiver of in-vivo bioavailability and 
bioequivalence studies for immediate release solid oral 
dosage forms based on a biopharmaceutics 
classification system (FDA, 2000) . 
The area under the dissolution-time curve method was 
used in calculating the dissolution efficiency (DE), and 
this was calculated at 30 min .The higher the 
dissolution efficiency (DE) is, the better the release 
efficiency of the tablets’ active ingredient, according to 
equation: 
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Where %D is the percentage dissolved at time t, % D 
(max) is the maximum dissolved at the final time T, 
and AUC (0-T) is the area under the curve from zero to 
time T
10,11
. 
Correlation calculation was carried out using MINI 
TAB14 specific statistical program. 
In vitro-In vivo relationship determination of level A 
correlation. 
In vivo percent absorbed of reference product was 
calculated by following equation: 
 
Where, 
𝐴𝑡
𝐴0
denotes the fraction of drug absorbed at time 
t, Ct is the plasma drug concentration at time t, Kel is 
elimination rate constant, AUC0-t and AUC0-∞ are the 
area under the plasma concentration– time profile 
curve at time t and ∞ respectively. Then the values of 
percent of drug released were plotted against the 
percent of drug absorbed for reference products of 
Atenolol using MINITAB14 analysis program to find 
out the relationship between data (correlation). 
 
RESULTS AND DISCUSSION 
A summary of the results of weight uniformity, 
hardness, friability, disintegration and assay are shown 
in Table 2. Weight uniformity may serve as a pointer to 
amount of the active pharmaceutical ingredient (API) 
contained in the formulation.  
Table 1: Weight uniformity of atenolol tablets 
Number of 
tablets 
Deviation 
(%) 
Average weight 
of tablets 
Minimum 18 
Maximum 20 
±10.0 
±20.0 
Less than 80 mg 
Minimum 18 
Maximum 20 
±7.5 
±15.0 
80mg to 250mg 
Minimum 18 
Maximum 20 
±5.0 
±10.0 
More than 
250mg 
All the brands complied with the compendial 
specification for weight uniformity. Hardness is 
referred to as non-compendial test. The hardness or 
crushing strength assesses the ability of dosage form to 
withstand handling without fracturing or chipping, It 
can also influence other parameters such as friability 
and disintegration. Hence, the dosage forms of all 
brands were satisfactory for hardness
7
. Friability test is 
used to evaluate the tablets resistance to abrasion. 
Friability is now included in the United States 
Pharmacopeia (USP, 1995) as a compendia test. The 
compendial specification for friability is less or equal 
to 1%. Friability for all brands of Atenolol was below 
1%. Disintegration is the process of breaking of tablets 
in the liquid. Disintegration is a crucial step for 
immediate release dosage forms because the rate of 
disintegration affects the dissolution and subsequently 
the therapeutic efficacy of the medicine. A drug will be 
released rapidly as the dosage forms disintegrate. 
British Pharmacopeia specifies that uncoated tablets 
should disintegrate within 15 min and film coated 
tablet disintegrate within 30 min while USP 
specification for disintegration is 30 min for both 
uncoated and film coated tablets. All the brands were 
complied with both BP and USP specifications for 
disintegration as maximum disintegration time. 
Potency is the average amount of the active ingredient 
present per tablet. All the brands complied both BP and 
USP specification, as USP specification is that the 
content of active ingredient should not be less than 
90% and not more than 110% while BP specifies that 
the content should not be less than 95% and not more 
than 105%. The results of dissolution studies are 
graphically represented in the Figure 1, Figure 2 and 
Figure 3. All dissolution data are based on the actual 
drug content of the test dosage form as calculated from 
the assay results. All Atenolol brands released about 
90% drug in PH (6.8), where about 87% in PH (4.5), 
reference drug released about 91% and test drug 
released about 87% in pH (1.2). To compare the 
dissolution profiles of the brands, a model independent 
approach of difference factor f1 and similarity factor f2 
were employed. Difference factor f1 is the percentage 
difference between two curves at each point and is a 
measurement of the relative error between the two 
curves. The similarity factor (f2) is a logarithmic 
reciprocal square root transformation of the sum of 
squared error and is a measurement of the similarity in 
the percent (%) dissolution between two curves. Two 
dissolution profiles to be considered similar and 
bioequivalent, f1 should be between 0 and 15 while f2 
should be between 50 and 100 (FDA, 1997). All the 
values for f2 and f1 shown in Table 3 for atenolol, all 
brands f2 values were more than 50 and f1 values were 
less than 15. It means that all brands were equivalent 
with the innovator brand. In-vitro AUC in three PH 
(1.2), (4.5), (6.8) for class III product, there was large 
difference between in-vitro AUC and in-vivo AUC , the 
in-vivo AUC is too small due to the lower permeability 
for this class of drug products , which will affect their 
AUC. Dissolution efficiency (DE) was also employed 
to compare the drug release from various brands. The 
reference and the test product can said to be equivalent 
if the difference between their dissolution efficiencies 
is within appropriate limits (±10%, which is often 
used).
Table 2: Quality control test results of atenolol brands 
Assay 
% 
Friability 
% 
Disintegration 
Time(min) 
Weight variation  
(RSD) 
Hardness 
(kg/cm) 
Brands 
99.88 0.01158 8:7 0.027 6.7 Sample (A) 
103 0.0184 6:6 0.185 5.9 Sample (B) 
 
Table 3: F1 and F2 values for Atenolol 
6.8 4.5 1.2 Samples  
 F2 F1 F2 F1 F2 F1 
87 2 92 1 71 3 Sample (B) 
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Figure 1: Dissolution profile of Atenolol in pH (1.2) 
Dissolution efficiency of the entire brands differed by 
less than 10% from the innovator brand. So, we can say 
that all the brands are pharmaceutically equivalent with 
the innovator brand
6
.  
 
Figure 2: Dissolution profile of Atenolol in pH (4.5) 
As IVIVC is a predictive mathematical model 
describing the relationship between variables (an in 
vitro property of a dosage form and a relevant in vivo 
response). According to MINITAM 14 statistical 
program, there was significant relationship between in 
vitro and in vivo data of reference Atenolol product, 
Correlation and distribution of data with correlation 
coefficient (r=0.798, 0.815, 0.967), non linear 
relationship with p-value (>0.05)=(0.106, 0.93, 0.009), 
there is no out lines, no lake of fits at P-Values=0.106, 
0.040, 0.056 (>0.05) for the three pH (1.2, 4.5, 6.8) 
respectively
8
. 
Estimating the uncertainty in predicted correlation 
between vitro and vivo data. The interval is represented 
by the curved lines on either side of the regression line 
and gives an indication of the range within which the 
‘true’ line might lie. Note that the confidence interval 
is narrowest near the center (the point x, y) and less 
certain near the extremes. 
By applying analysis of variance (ANOVA) for the 
dissolution data using MINITAB 14 we concluded that 
the test products are bioequivalent to reference 
products of Atenolol and could be interchangeable.  
 
CONCLUSION 
The bio waiver study has emphasized that 
pharmaceutical equivalence indicate that product have 
same drug molecule with approximately same pattern 
of dissolution release profile. By making fine turning in 
bioequivalent study we can reduce the time, cost, avoid 
Ethical, Ethnical consideration by unnecessary 
exposure of healthy subjects to medicines and finally to 
market the quality generic drug product. By applying 
level A in vitro-in vivo correlation, study concluded 
that there is no linear correlation between percent of 
drug released and percent of drug absorbed ,this may 
be due to uncontrollable permeability rate for class 
three Atenolol. Atenolol are immediate release 
formulations. As dissolution is not a rate-limiting step 
in IR products, the fraction of drug absorbed against 
the fraction of drug released profile would be non-
linear type which was obtained in present study. So it 
may be concluded that the In vitro-in vivo correlation is 
well established and justified for both reference 
formulations by level A correlation. 
 
Table 4: Dissolution efficiency for Atenolol brands 
6.8 4.5 1.2 Brands 
Difference 
with 
reference 
AUC Difference 
with 
reference 
AUC Difference 
with 
reference 
AUC  
- 364.69 - 357.68 - 348.83 Brand (A) 
-5.26 359.43 1.75 355.93 -9.22 358.05 Brand (B ) 
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     Figure 3: Dissolution profile of Atenolol in pH (6.8)                   Figure 4: Atenolol correlation at pH (1.2) 
    
Table 5:  Relative dissolution efficiency of sample (B) 
6.8 4.5 1.2 PH 
98.56 99.51 102.64 % 
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          Figure 5: Atenolol correlation at pH (4.5)                                       Figure 6: Atenolol correlation at pH (6.8) 
By applying analysis of variance (ANOVA) for the 
dissolution data using MINITAB 14 we concluded that 
the test products are bioequivalent to reference 
products of Atenolol and could be interchangeable.  
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